{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hoti N"],"funding":["Flight Attendant Medical Research Institute","National Cancer Institute, the Early Detection Research Network","NCI NIH HHS"],"pagination":["817-829"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5587889"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(10)"],"pubmed_abstract":["Although XPO5 has been characterized to have tumor-suppressor features in the miRNA biogenesis pathway, the impact of altered expression of XPO5 in cancers is unexplored. Here we report a novel \"oncogenic\" role of XPO5 in advanced prostate cancer. Using prostate cancer models, we found that excess levels of XPO5 override the inhibitory effect of the canoncial miRNA-mRNA regulation, resulting in a global increase in proteins expression. Importantly, we found that decreased expression of XPO5 could promote an increase in proteasome degradation, whereas overexpression of XPO5 leads to altered protein posttranslational modification via hyperglycosylation, resulting in cellular protein stability. We evaluated the therapeutic advantage of targeting XPO5 in prostate cancer and found that knocking"],"journal":["Neoplasia (New York, N.Y.)"],"pubmed_title":["Overexpression of Exportin-5 Overrides the Inhibitory Effect of miRNAs Regulation Control and Stabilize Proteins via Posttranslation Modifications in Prostate Cancer."],"pmcid":["PMC5587889"],"funding_grant_id":["U01CA152813","R01 CA121153","U01 CA152813"],"pubmed_authors":["Eroglu AU","Chowdery WH","Hu Y","Hoti N","Shah P","Zhang H","Aiyetan P","Johnson T","Clark D","Yang S","Kumar B","Rodriguez R"],"additional_accession":[]},"is_claimable":false,"name":"Overexpression of Exportin-5 Overrides the Inhibitory Effect of miRNAs Regulation Control and Stabilize Proteins via Posttranslation Modifications in Prostate Cancer.","description":"Although XPO5 has been characterized to have tumor-suppressor features in the miRNA biogenesis pathway, the impact of altered expression of XPO5 in cancers is unexplored. Here we report a novel \"oncogenic\" role of XPO5 in advanced prostate cancer. Using prostate cancer models, we found that excess levels of XPO5 override the inhibitory effect of the canoncial miRNA-mRNA regulation, resulting in a global increase in proteins expression. Importantly, we found that decreased expression of XPO5 could promote an increase in proteasome degradation, whereas overexpression of XPO5 leads to altered protein posttranslational modification via hyperglycosylation, resulting in cellular protein stability. We evaluated the therapeutic advantage of targeting XPO5 in prostate cancer and found that knocking","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Oct","modification":"2025-04-19T14:10:23.912Z","creation":"2019-03-27T02:55:41Z"},"accession":"S-EPMC5587889","cross_references":{"pubmed":["28881308"],"doi":["10.1016/j.neo.2017.07.008"]}}